Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab in Subjects with Active Lupus Nephritis
2018-003155-38Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in lupus nephritis (LN) comparing Guselkumab with Placebo (2 arms). Primary endpoint: Proteinuria reduction. Started Jun 2020; status: completed.
02
Drugs
guselkumab
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on 2018-003155-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003155-38.